zum Inhalt
Header Image

Ph.D. Dr. rer. nat. habil. Walter H. GÜNZBURG Professor of Virology and Head, Institute of Virology, University of Veterinary Sciences, Vienna


 Received his Ph.D. in London on the control of eukaryotic gene expression by DNA methylation. After two postdoctoral positions in the U.S.A. and Switzerland, he became a group leader at the National Research Centre for Environment and Health (GSF), in Munich, Germany where he spent 8 years working on retroviral vector mediated gene therapy as well as continuing his basic studies on gene expression control in retroviruses. In 1996, he was appointed full Professor of Virology in Vienna, Austria and since then has headed the Research Institute of Virology and Biomedicine in Vienna. In 2004, he additionally became the head of the newly established Christian Doppler Laboratory for Gene Therapeutic Vector Development, working in close collaboration with Biotech and Pharmaceutical industries to develop new retroviral vectors and cell therapy approaches for the treatment of solid tumours. In 2007 the Christian Doppler Society opened a foreign module focusing on virology and nanotechnology in Singapore under his leadership. Over the last ten years Prof Günzburg has been actively involved in European ethics and regulatory affairs in the fields of both xenotransplantation and gene therapy.


Faculty Member of The European Academy for the Study of Consequences of Scientific and Technological Advance
Member of the American Society of Gene Therapy and of the European Working Group, Human Gene Transfer and Therapy, now European Society for Gene Therapy. Previously he also was Chief Scientific Advisor to the listed company Bavarian Nordic A/S, as well as Chairman of the Board of Austrianova, a cell therapy company and ViruSure, a prion and virus clearance service provider company. He was also the founding member of the Austrian Network for Gene Therapy.


Over 120 peer-reviewed publications, 120 invited talks, 180 conferences, 20 book chapters and 2 books on retroviruses and/or xenotransplantation.


12 International Patent Families applied for or granted and around 25 grants awarded (academic, international, industrial)